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A recently described protein module consisting of
35–40 semiconserved residues, termed the WW domain,
has been identified in a number of diverse proteins in-
cluding dystrophin and Yes-associated protein (YAP).
Two putative ligands of YAP, termed WBP-1 and WBP-2,
have been found previously to contain several short
peptide regions consisting of PPPPY residues (PY motif)
that mediate binding to the WW domain of YAP. Al-
though the function(s) of the WW domain remain to be
elucidated, these observations strongly support a role
for the WW domain in protein-protein interactions. Here
we report the isolation of three novel human cDNAs
encoding a total of nine WW domains, using a newly
developed approach termed COLT (cloning of ligand
targets), in which the rapid cloning of modular protein
domains is accomplished by screening cDNA expression
libraries with specific peptide ligands. Two of the new
genes identified appear to be members of a family of
proteins, including Rsp5 and Nedd-4, which have ubiq-
uitin-protein ligase activity. In addition, we demon-
strate that peptides corresponding to PY and PY-like
motifs present in several known signaling or regulatory
proteins, including RasGAP, AP-2, p53BP-2 (p53-binding
protein-2), interleukin-6 receptor-a, chloride channel
CLCN5, and epithelial sodium channel ENaC, can selec-
tively bind to certain of these novel WW domains.
The recognition and elucidation in recent years of various
modular protein domains, along with their specific peptide
ligands, have spawned a remarkable progress in our under-
standing of their role in signal transduction and other funda-
mental cellular processes (1, 2). Analysis of the SH (Src homol-
ogy) domains, SH2 and SH3, present in a wide variety of
proteins involved in cellular signaling and transformation has
been particularly fruitful. The ligand specificity of many differ-
ent SH2 and SH3 domains has been defined using combinato-
rial peptide libraries. SH2 domains bind with high affinity to
phosphotyrosine residues within a specific sequence context
(3). In contrast, SH3 domains bind to proline-rich peptides that
share a conserved PXXP motif (4, 5).
A newly described protein module, termed the WW domain,
has been reported (6–8). The WW domain consists of 35–40
amino acids and is characterized by four well conserved aro-
matic residues, two of which are tryptophan. The secondary
structure of the WW domain has recently been determined and
consists of a slightly bent three-stranded antiparallel b-sheet
(9). This domain has been reported in a wide variety of proteins
of yeast, nematode, and vertebrate origin, including Rsp5, Yes-
associated protein (YAP),1 human and murine Nedd-4, FE65,
Pin1, and a human RasGAP-related protein (10–14). Although
the precise physiological role of the WW domain remains un-
determined, its presence in diverse proteins involved in signal-
ing, regulatory, and cytoskeletal functions, as well as its rap-
idly emerging role in signaling mechanisms that underlie
several human diseases, clearly underscores its importance
(15, 16). Two ligand proteins for the YAP WW domain, WBP-1
and WBP-2 (WW domain-binding protein), have recently been
cloned and found to contain a run of prolines followed by a
tyrosine residue (PY motif) that mediate specific binding to the
YAP WW domain (17). It is likely that WW domains have
distinct ligand specificities, as the PY motifs of WBP-1 and
WBP-2 did not bind to the dystrophin WW domain. Further-
more, the PY motif appears to be distinct from the PXXP ligand
consensus sequence of SH3 domains. These observations sug-
gest a direct role for the WW domain in mediating specific and
distinct protein-protein interactions.
Recently, we described a method termed COLT (cloning of
ligand targets), which enables the rapid cloning of ligand-
binding modular protein domains using peptide ligand se-
quences as probes for screening cDNA expression libraries (18).
While COLT has been used to clone several novel SH3 domain-
containing genes using proline-rich SH3 domain ligand pep-
tides as probes, in this report, we describe its use in identifying
three novel human WW domain-containing genes. In examin-
ing the ligand specificity of the individual WW domains, we
demonstrate that they bind distinct PY motif peptide ligands
with differential specificity and relative affinity. In addition,
we demonstrate that peptides containing PY and PY-like mo-
tifs present in a variety of signaling or regulatory proteins can
selectively bind to these novel WW domains.
EXPERIMENTAL PROCEDURES
Isolation and Characterization of WW Domain-encoding cDNA
Clones by COLT—All peptides used were synthesized with an N-termi-
nal biotin-SGSG linker and purified by high pressure liquid chroma-
tography, and their structures were confirmed by mass spectroscopy
and amino acid analysis. Multivalent peptide-streptavidin/alkaline
phosphatase complexes were assembled as described (18) with the
exception of the phosphotyrosine-containing peptide (pWBP-1), for
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which a streptavidin-horseradish peroxidase conjugate was used (Sig-
ma). Human bone marrow and brain l cDNA libraries (CLONTECH,
Palo Alto, CA) were plated at a density of ;1 3 105 plaque-forming
units/10-cm plate, and positive plaques were detected and purified as
described previously (15). Bound streptavidin-horseradish peroxidase
conjugate was detected with the IBI Enzygraphic™ Web (Kodak Scien-
tific Imaging Systems) as described by the manufacturer. DNA was
sequenced on both strands using ABI PRISM™ dye terminator cycle
chemistry (Perkin-Elmer) on an ABI 373A automated DNA sequencer.
Preparation of WW Domain-GST Fusion Proteins and Peptide Cross-
affinity Mapping—Polymerase chain reaction fragments encoding indi-
vidual WW domains were subcloned into the SalI and NotI sites of
pGEX-4T-2 (Pharmacia Biotech Inc.), and fusion proteins were ex-
pressed and purified as described by the manufacturer. Enzyme-linked
immunosorbent assay-based cross-affinity experiments were performed
essentially as described (5), with the following modifications. Briefly,
microtiter wells were coated with 1–5 mg of fusion protein in 100 mM
NaHCO3, blocked with SuperBlock Tris-buffered saline (Pierce), and
washed four times with phosphate-buffered saline and 0.05% Tween 20.
Specific peptide-streptavidin/alkaline phosphatase complexes were
added as described above, and unbound complexes were washed five
times with phosphate-buffered saline and 0.05% Tween 20. Following
addition of p-nitrophenyl phosphate substrate (Kirkegaard & Perry
Laboratories), peptide binding was quantitated after 30 min at A405 nm.
Relative binding measurements from three independent determina-
tions were assigned to a scale as follows: A units of 0–0.5 5 (2),
0.5–1.0 5 (1), 1.0–2.0 5 (11), 2.0–3.0 5 (111), and . 3.0 5 (1111).
Peptide binding to full-length human Fyn and Lyn was assessed by a
filter binding assay (5). Peptide sequences used in cross-affinity exper-
iments correspond to segments of the following proteins: RasGAP
(GenBank accession number P20936); the AP-2 transcription factor
(P05549); p53BP-2 (p53-binding protein-2) (U09582); interleukin-2 re-
ceptor-g (D11086); interleukin-6 receptor-a (P22272); voltage-gated
chloride channel CLCN5 (X91906); Rous sarcoma virus Gag (D10652);
human T-cell lymphotropic virus type 1 Gag (D13784); b-dystroglycan
(L19711); Formin (X53599); amiloride-sensitive epithelial Na1 channel
ENaCa (P37089), ENaCb (X87159), and ENaCg (X87160); muscarinic
acetylcholine receptor M4 (P08173); and c-Abl (P00522). Src and Crk
SH3-binding peptide sequences were derived from a phage display
random peptide library screen (5). Protein sequence homology searches
were performed using BLAST (19) and PROFILES (20) programs.
RESULTS AND DISCUSSION
Isolation of Novel WW Domain-containing Proteins—In an
effort to identify novel WW domain-containing proteins, four
putative WW domain peptide ligand sequences including
WBP-1 (PGTPPPPYTVGPGY), WBP-2A (YVQPPPPPYPGPM),
WBP-2B (PGTPYPPPPEFY), and a PY peptide segment of Ras-
GAP (GGGFPPLPPPPYLPPLG) were used as a mixed probe to
screen human brain and bone marrow cDNA expression librar-
ies by COLT. Thirteen positive clones were identified, includ-
ing sibling and overlapping clones originating from the same
mRNA. These clones were sequenced and found to encode three
distinct proteins, WWP1, WWP2, and WWP3 (WW domain-
containing protein), containing a total of nine novel WW do-
mains (Fig. 1). Data base homology searches revealed that both
WWP1 and WWP2 contain four tandem WW domains and
share a similar modular domain architecture with Nedd-4 and
Rsp5 (10). The smaller partial clone, WWP3, was isolated from
the brain cDNA library and contains a single WW domain.
In addition to the high overall amino acid homology (55%),
alignment of the nine novel WW domain sequences with sev-
eral previously identified domains reveals two significant
blocks of homology flanking the core of the domain (Fig. 2).
These blocks include N-terminal tryptophan and C-terminal
proline residues that are absolutely conserved in all WW do-
mains identified to date. The WW domains of WWP1, WWP2,
WWP3, Nedd-4, Rsp5, and YAP are more similar to each other
than to WW domains found in other proteins (21). Further-
more, contrary to what one would expect from a recent evolu-
tionary duplication event of the WW domain within a gene,
individual WW domains from WWP1 and WWP2 show a
greater similarity to the corresponding WW domains in either
Nedd-4 or Rsp5 than to each other. The above observations
suggest that these WW domains are perhaps functionally sim-
ilar and that multiple WW domains within the same protein
are not redundant but may have evolved to perform divergent
specialized roles. Interestingly, we did not isolate a human
YAP cDNA from these screens. However, murine YAP was
detected in a screen of a mouse embryonic cDNA library with
the WBP-2A peptide as a COLT probe.2
In addition to the WW domains, primary structure analysis
of the clones revealed several other interesting features. Com-
plete and partial C-terminal HECT (homologous to the E6-
associated protein carboxyl terminus) domains of ;300 amino
acids (Fig. 3) are contained within clones WWP2 and WWP1,
respectively. This domain has been shown in vitro to have E3
ubiquitin-protein ligase activity in several proteins including
rat p100, yeast Rsp5, and human papilloma virus E6-AP (22,
23). Encoded within the last 40 amino acids of the HECT
domain is a conserved cysteine residue that is the likely site for
ubiquitin thioester formation. The presence of a HECT domain
is noteworthy since structurally and functionally related E3
ubiquitin-protein ligases are thought to serve a major role in
defining the substrate specificity of the ubiquitin degradation
system (24). In fact, Rsp5 was recently shown to be involved in
the induced degradation of several nitrogen permeases in yeast
(25). WWP2 also encodes an N-terminal C2-like domain char-
acteristic of a large family of proteins including protein kinase
C (26) and synaptotagamins (27). The C2 domain has been
shown to bind membrane phospholipids in a calcium-depend-
ent manner and is thought to function in the intracellular
compartmentalization of proteins (28). Although the different
modular domains present within WWP1 and WWP2 are highly
homologous to those found in Nedd-4 and Rsp5, there is no
significant homology among these proteins in regions flanking
these domains. Also of interest is the presence in clone WWP3
2 R. Gao and B. K. Kay, unpublished data.
FIG. 1. Schematic representation of
the modular architecture of novel
WW domain-containing genes iso-
lated by COLT. The relative location
and size of various modular protein do-
mains including the WW, E3 ubiquitin-
protein ligase (HECT), phospholipid-
binding (C2), and guanylate kinase-like
(GK) domains are shown within the pro-
tein-coding regions of WWP1, WWP2, and
WWP3. Arrows denote incomplete N- and
C-terminal coding sequences. aa, amino
acids.
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of a partial N-terminal guanylate kinase-like domain that is
involved in GMP binding in several membrane-associated pro-
teins including the human erythrocyte membrane protein p55
(29) and rat postsynaptic density protein PSD-95 (30).
WW Domain-Peptide Ligand Selectivity—To examine the
peptide ligand binding preferences of all nine individual novel
WW domains, an enzyme-linked immunosorbent assay-based
cross-affinity map experiment was performed with each do-
main expressed as a GST fusion protein and WBP-derived
peptides (Fig. 4). Peptides WBP-1, WBP-2A, and WBP-2C
bound to several individual WW domains to varying degrees.
The WBP-2B peptide with an N-terminal tyrosine residue rel-
ative to the run of prolines had no binding activity, indicating
the necessity for a C-terminal tyrosine in the PY motif. The
relative importance of individual proline residues within the
PY motif for binding to various WW domains was assessed by
alanine substitution for both the WBP-1 and WBP-2A peptides.
All of the variant WBP-1 peptides, with the exception of the
third proline substitution (WBP-1-Pro3), retained binding ac-
tivity to WW domains present in clones WWP1 and WWP2,
suggesting a critical role for the third proline residue. Interest-
ingly, substitution of the second proline residue (WBP-1-Pro2)
did not abolish binding to WW domains WWP1.1 and WWP2.3.
This was unanticipated in light of the results observed for
binding of the WBP-1 protein PY motif to the YAP WW domain,
in which both the second and third proline residues are crucial
for binding (9, 17). This difference suggests that WW domains
WWP1.1 and WWP2.3 possess a more promiscuous binding
specificity than does the YAP WW domain. Similarly, proline
substitution of the WBP-2A peptide indicates that the third
proline residue (WBP-2A-Pro3) is absolutely essential for WW
domain binding, whereas substitution of the second proline
(WBP-2A-Pro2) is not.
The specificity of individual WW domains for PY motif se-
quences was demonstrated by the ability to discriminate be-
tween peptides containing SH3 domain PXXP ligand consensus
sequences (Src and Crk) as well as generally proline-rich con-
trol peptides derived from several proteins including acetylcho-
line receptor M4 and c-Abl. In addition, none of the PY motif
peptides bound to either full-length Fyn or Lyn (which contain
both SH3 and SH2 domains) in filter binding assays. Taken
together, these results suggest that the PY motif represents a
distinct binding sequence for WW domains.
The presence of a critical tyrosine residue in the PY motif
raised the question of whether tyrosine phosphorylation could
modulate WW domain binding. Although it is not known
whether PY motifs are phosphorylated in vivo, the presence of
a phosphotyrosine residue in the pWBP-1 peptide abolishes
WW domain binding. Moreover, binding of the pWBP-1 peptide
could be restored by removal of the phosphate moiety with
prior treatment of either the free peptide or peptide bound to a
streptavidin-horseradish peroxidase conjugate with alkaline
phosphatase (data not shown). These results suggest a poten-
tial regulatory role for tyrosine phosphorylation in modulating
WW domain-ligand interactions.
Potential WW Domain-PY Motif Interactions—Data base
searches revealed that PY and PY-like motif sequences are
found in a wide variety of regulatory proteins. Included among
these proteins are the GTPase-activating protein RasGAP, the
AP-2 transcription factor, p53BP-2, renal chloride channel
CLCN5, the dystrophin-interacting molecule b-dystroglycan,
the interleukin-2 receptor and interleukin-6 receptor-a, and
the retroviral Gag proteins from human T-cell lymphotropic
virus type 1 and Rous sarcoma virus type 1 (30–36). We tested
the ability of peptides containing these motifs to bind to the
novel WW domains (Fig. 5). Interestingly, although all of these
peptides displayed an ability to bind WW domains in general,
differences in specificity and relative binding were evident. For
example, of all the peptides tested, only the CLCN5 peptide
showed appreciable binding to the WWP1.4 and WWP2.4 do-
mains. The observation that PY motif-containing peptides from
several other proteins did not bind to any WW domain tested
indicates that these interactions are specific and potentially
biologically relevant (data not shown).
Of particular note is the demonstration that the human
T-cell lymphotropic virus type 1 and Rous sarcoma virus type 1
peptides derived from the Gag protein proline-rich “L domain”
bound to several WW domains. L domain regions are highly
conserved in retroviruses and have been shown to function in a
positionally independent manner essential for retroviral bud-
ding (37). Our results, coupled with a recent report demonstrat-
ing the interaction of the YAP WW domain with the L domain
of Rous sarcoma virus (38), suggest a direct role for a WW
domain(s)-Gag protein interaction in this process. The interac-
tion of a b-dystroglycan peptide with several WW domains is
also of interest. b-Dystroglycan, which contains a C-terminal
PY motif, was previously shown to interact with the single WW
domain present in dystrophin (15). Our results suggest that
perhaps several different WW domain-containing proteins can
interact with the b-dystroglycan C-terminal PY motif. Re-
cently, a 12-amino acid proline-rich region of Formin, a protein
encoded by the mouse limb deformity locus (39), was shown to
bind to both SH3 domain- and several novel WW domain-
containing proteins (40). Significantly, a peptide encompassing
the same proline-rich region of Formin did not bind to any of
our novel WW domains. Since this peptide does not contain a
PY motif, this suggests that our WW domains, unlike those
present in the Formin-binding proteins, require a PY or PY-like
motif for binding.
Taken together, the above observations suggest that inter-
actions between these proteins and WW domain-containing
proteins may play a role in the former’s regulation in vivo. For
example, given the likelihood that WWP1 and WWP2 function
as E3 ubiquitin-protein ligases, one could invoke a simple
model whereby initial substrate-specific recognition occurs via
WW domain-substrate protein interaction followed by ubiq-
uitin transfer and subsequent proteolysis. On a general level,
FIG. 2. Deduced amino acid sequence and alignment of novel
WW domains. The name, species, amino acid position (if known), WW
domain sequence, and accession number of representative WW domain
sequences are shown. Amino acids conserved in .75% of the sequences
are shaded. The consensus shows conserved amino acids including
hydrophobic (h) and polar (t) residues.
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the identification of WW domain PY motif ligand sequences in
various candidate proteins can lead to testable predictions of
specific WW domain-mediated interactions in vivo.
WW Domain-Epithelial Na1 Channel Interactions—The
demonstration that peptides containing PY-like motifs derived
from the cytoplasmic domains of both the wild-type b- and
g-subunits of the epithelial Na1 channel (ENaCb-WT and
ENaCg-WT) bind to several WW domains is of particular in-
terest (Fig. 6). Recently, a number of mutations in both ENaCb
and ENaCg have been demonstrated in patients with an auto-
somal dominant form of hypertension characterized by ele-
vated renal Na1 reabsorption, termed Liddle syndrome (41).
Specifically, several nonsense mutations leading to the trunca-
tion of the cytoplasmic domain of both subunits, in addition to
two missense mutations (P616L and Y618H) contained within
a conserved proline-rich segment of the cytoplasmic domain of
the b-subunit, have been identified in patients (42–44). More-
over, expressed proteins containing these mutations resulted in
a 3–8-fold increase in ENaC activity that was directly related
to an increase in the total number of active channels. These
results suggest the hypothesis that specific cytoplasmic regions
of the b- and g-subunits are involved in the normal negative
regulation of channel activity via interactions with a modula-
tory protein(s). In fact, Nedd-4 was recently identified as a
binding partner with the C terminus of rat ENaCb using the
yeast two-hybrid system (45, 46). In addition, we have recently
FIG. 3. Alignment of WWP1 and WWP2 with representative C-terminal HECT domains. The C-terminal 100 amino acids of HECT
domain-containing genes are shown aligned with the partial and complete C termini of WWP1 and WWP2, respectively. Completely and partially
(.60%) conserved residues are shaded and in boldface, respectively. The asterisk denotes the conserved cysteine residue that serves as a site for
ubiquitin thioester formation.
FIG. 4. WW domain-WBP peptide interactions. Biotinylated peptides were tested for their relative binding to individual WW domains
expressed as GST fusion proteins and to full-length Fyn and Lyn in filter binding assays (see “Experimental Procedures”). PY and PY-like motifs
within the peptide sequences are underlined, and specific alanine substitution variants of the WBP-1 and WBP-2A peptides are indicated in
boldface. pWBP-1 denotes phosphotyrosine-containing peptide. Relative binding was assessed from three independent determinations. All PY
motif peptides displayed no detectable binding to GST control protein or to bovine serum albumin. AChR, acetylcholine receptor.
FIG. 5. Naturally occurring WW domain-PY motif interactions. PY and PY-like motif peptides derived from representative proteins (see
“Experimental Procedures”) were tested for their relative binding to WW domain-GST fusion proteins. IL-2Rg and IL-6Ra, interleukin-2 receptor-g
and interleukin-6 receptor-a, respectively; HTLV-1, human T-cell lymphotropic virus type 1; RSV-1, Rous sarcoma virus type 1.
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isolated WWP1 in COLT screens using ENaCb and ENaCg
peptides (data not shown).
Our observation that mutant peptides (ENaCb-P616L and
ENaCb-Y618H) containing missense substitutions found in
Liddle syndrome patients do not bind to the WW domains in
clones WWP1 and WWP2 is consistent with the above hypoth-
esis. This result also confirms the observation that the third
proline residue and the tyrosine within the PY motif are critical
for binding to the WW domain. Other substitutions of the
b-subunit PY motif and flanking sequences were also shown to
diminish binding to specific WW domains. Thus, substitution of
the second proline residue of the core PY motif completely
abrogated WW domain binding. In addition, mutation of spe-
cific residues flanking the C terminus of the PY motif also led
to diminished WW domain binding. These results directly cor-
relate with the activity of various ENaCb mutants measured
by a functional assay in Xenopus oocytes (47). A PY motif-
containing peptide from the cytoplasmic domain of the wild-
type a-subunit of ENaC (ENaCa-WT) was also shown to bind to
several WW domains, suggesting that this subunit may also be
regulated by a WW domain-mediated interaction(s). Taken to-
gether, the above observations suggest a mechanism whereby a
WW domain-mediated interaction(s) of a Nedd-4 family mem-
ber(s) leads to the eventual ubiquitin-mediated degradation
and negative regulation of the Na1 channel.
We have used the COLT approach to identify two new mem-
bers (WWP1 and WWP2) of a family of human Nedd-4-like
proteins associated with ubiquitin-protein ligase activity.
Moreover, we demonstrate that individual WW domains of
these proteins can clearly bind distinct PY motif peptide li-
gands with differential specificity and relative affinity. In ad-
dition to demonstrating the expanded utility of COLT method-
ology, it appears likely that additional proteins containing the
modular WW domain remain to be found. In fact, we have
recently isolated a third novel Nedd-4-like family member,
containing three WW domains, from a human prostate cDNA
library.3 Our results, coupled with knowledge of the NMR
structure of the WW domain-ligand complex, provide a frame-
work with which to examine the peptide ligand specificity and
structure/function activity of individual WW domains. In this
regard, optimal ligand preferences of the WW domains are
currently being deduced by screening combinatorial phage dis-
play peptide libraries.4 Given the small size and high degree of
sequence conservation of the WW domain, it is extraordinary
that exquisite ligand selectivity is observed. The NMR struc-
ture of the human YAP WW domain and its peptide ligand
reveals that the hydrophobic residues Leu-190, His-192, and
Trp-199 (see Fig. 2) form a binding site in contact with the
ligand (9). In light of these data, it is interesting to note that
domains WWP1.4 and WWP2.4, which contain a C-terminal
phenylalanine residue instead of a tryptophan, display a more
restrictive ligand binding preference. In addition, the presence
of a valine or isoleucine residue instead of Leu-190 may also
play a role in determining the distinct ligand specificity of the
novel WW domains. The presence of multiple WW domains
with distinct ligand specificities in WWP1 and WWP2 suggests
that these proteins may bind to a broad range of cellular
targets. Alternatively, multiple WW domains may confer addi-
tive binding affinity to target molecules that contain multiple
PY motif ligands.
Finally, the interaction of peptides containing PY and PY-
like motifs from several proteins with the WW domains in
WWP1 and WWP2 directly suggests a role for the ubiquitin-
mediated degradation of these proteins. In this respect, it is
noteworthy that several cell membrane proteins, including the
platelet-derived growth factor receptor (48) and yeast a-factor
receptor Ste2p (49), are subject to ubiquitination and eventual
degradation upon ligand binding. This is particularly relevant
in light of the observed interaction of PY motif-containing
peptides from ENaC subunits with specific WW domains and
may lead to an understanding of the molecular pathology of
Liddle syndrome.
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R. (1995) Cell 80, 929–938
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